Segment Information

9 Months Ended

Mar. 31, 2018

Note 12. Segment Information

The Company operates in one reportable segment (oncology systems group), which develops, manufactures and markets proprietary medical devices used in radiation therapy and radiosurgery for the treatment of cancer patients. The Company’s Chief Executive Officer, its Chief Operating Decision Maker, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance. The Company does not assess the performance of its individual product lines on measures of profit or loss, or asset-based metrics.

The following tables present net revenue and long-lived asset information based on geographic region. Net revenue is based on the destination of the shipments and long-lived assets are based on the physical location of the assets (in thousands):

	Three Months Ended March 31,				Nine Months Ended March 31,
Net Revenue	2018		2017		2018		2017
Americas	$	41,767	$	38,720	$	115,544	$	118,545
Europe, Middle East, India and Africa		14,731		21,785		81,885		68,705
Asia-Pacific and Japan		43,334		36,807		93,682		84,070
Total	$	99,832	$	97,312	$	291,111	$	271,320

	March 31,		June 30,
Property and equipment, net	2018		2017
Americas	$	19,958	$	18,435
Europe, Middle East, India and Africa		665		730
Asia-Pacific and Japan		3,839		3,897
Total	$	24,462	$	23,062